Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on the shares. The firm is also updating its Myriad estimates to account for lower pharmacogenomics revenue following the dropping of GeneSight coverage by United Healthcare.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics unveils resesrch at SMFM on cfDNA
- Myriad Genetics introduces online prenatal genetic testing resource
- Myriad Genetics announces hereditary cancer risk assessment study published
- Myriad Genetics sees Q4 adjusted EPS 3c-4c, consensus 3c
- Myriad Genetics sees FY24 adjusted EPS 14c-15c, consensus 13c